- Home
- CABR vs ATHA Comparison
CABR vs ATHA Comparison
Compare CABR & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABR | ATHA |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 18.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CABR | ATHA |
|---|---|---|
| Price | $1.34 | $4.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 710.2K | 18.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,493.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $2.20 |
| 52 Week High | $6.00 | $6.50 |
Technical Indicators
Market Signals| Indicator | CABR | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.25 |
| Support Level | N/A | $3.84 |
| Resistance Level | N/A | $4.74 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 26.85 |
Price Performance
Historical ComparisonAbout CABR Caring Brands Inc. Common Stock
Caring Brands Inc is a consumer wellness company specializing in over-the-counter (OTC) and cosmetic products.support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. It product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Company's majority of revenue is generated through the sales of OTC and consumer products and licensing royalties.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.